LAS VEGAS, NV—(Marketwired – April 10, 2018) – CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a development stage diversified cannabis company operating as Cannabis Life Sciences, is pleased to announce its strategy to monetize its proprietary conversion and extraction process. CLS has received a patent allowance in the United States with respect to its proprietary conversion and extraction process and has made additional patent filings in Canada and the 38 countries that are part of the European Patent Organization. As a result, the Company has begun dialogue with a number of cultivators to license its conversion and extraction process that is the subject of its patent allowance.
Jeff Binder, Chairman and CEO, stated, “This is a very exciting time for CLS as we will begin discussions to monetize our proprietary conversion and extraction process. We are thankful to have been issued a patent allowance on December 24th, 2017 and are eager to introduce our conversion and extraction process to the multi–billion dollar global cultivation market. Our methodology, which utilizes the entire plant has shown a higher concentration of Delta9THC and yields that are 2x those of conventional methods.”
About CLS Holdings USA (www.clsholdingsinc.com)
CLS Holdings USA, Inc. (OTCQB: CLSH) plans to become a diversified cannabis company and is shifting its corporate strategy to becoming a fully licensed integrated cannabis producer and retailer in Nevada and other states.
CLS stands for “Cannabis Life Sciences,” in recognition of the Company's proprietary method of extracting various cannabinoids from the marijuana plant and converting them into products with a higher level of quality and consistency. The Company's business model includes licensing operations, processing operations, processing facilities, sale of products, brand creation and consulting services.
For additional information, please visit: http://www.clsholdingsinc.com
Forward Looking Statements
This press release contains forward–looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to anticipated future events, future results of operations or future financial performance. These forward–looking statements include, but are not limited to, statements relating to whether certain transactions will be completed, the terms of such transactions, the descriptions of the companies and the business that any potential target companies could bring to CLS Holdings. In some cases, you can identify forward–looking statements by terminology such as “may,” “might,” “will,” “should,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These forward–looking statements are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward–looking statements. We cannot guarantee future results, levels of activity or performance and we cannot guarantee that the proposed transactions described in this press release will occur. You should not place undue reliance on these forward–looking statements, which speak only as of the date that they were made. These cautionary statements should be considered together with any written or oral forward–looking statements that we may issue in the future. Except as required by applicable law, we do not intend to update any of the forward–looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events. CLS Holdings USA has entered into a definitive agreement to acquire Oasis Cannabis, which is expected to close in the second quarter of 2018. See CLS Holdings USA filing with the SEC for additional details.